Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally …
H Wang, H Tang, Y Fang, L Tan, J Yin, Y Shen… - JAMA …, 2021 - jamanetwork.com
Importance Safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) vs neoadjuvant
chemotherapy (nCT) for treatment of locally advanced esophageal squamous cell carcinoma (…
chemotherapy (nCT) for treatment of locally advanced esophageal squamous cell carcinoma (…
Robot-assisted versus conventional minimally invasive esophagectomy for resectable esophageal squamous cell carcinoma: early results of a multicenter randomized …
Y Yang, B Li, J Yi, R Hua, H Chen, L Tan, H Li, Y He… - 2022 - journals.lww.com
Objective: To compare perioperative and long-term outcomes of robot-assisted minimally
invasive esophagectomy (RAMIE) and conventional minimally invasive esophagectomy (MIE) …
invasive esophagectomy (RAMIE) and conventional minimally invasive esophagectomy (MIE) …
[HTML][HTML] Dissecting the single-cell transcriptome network underlying esophagus non-malignant tissues and esophageal squamous cell carcinoma
…, T Lu, Q Sui, C Zhan, M Lin, W Guo, Q Wang, L Tan - …, 2021 - thelancet.com
Background Esophageal squamous cell carcinoma (ESCC) is among the most prevalent
causes of cancer-related death in adults. Tumor microenvironment (TME) has been associated …
causes of cancer-related death in adults. Tumor microenvironment (TME) has been associated …
Single-versus multiple-port thoracoscopic lobectomy for lung cancer: a propensity-matched study
Y Shen, H Wang, M Feng, Y Xi, L Tan… - European Journal of …, 2016 - academic.oup.com
OBJECTIVES In this retrospective study, we aimed to compare single-port (SP) and
multiport (MP) video-assisted thoracoscopic surgery (VATS) for the surgical resection of non-small-…
multiport (MP) video-assisted thoracoscopic surgery (VATS) for the surgical resection of non-small-…
[HTML][HTML] LncRNA FAM83A-AS1 facilitates tumor proliferation and the migration via the HIF-1α/glycolysis axis in lung adenocarcinoma
…, T Lu, C Zhan, Z Lin, F Sun, Q Wang, L Tan - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
… Li, Jiaqi Liang, Tao Lu, Cheng Zhan, ✉ Zongwu Lin, ✉ Fenghao Sun, ✉ Qun Wang, and Lijie
Tan … Lijie Tan supervised this study. All authors read and approved the final version of the …
Tan … Lijie Tan supervised this study. All authors read and approved the final version of the …
[HTML][HTML] miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
…, Y Huang, V Besskaya, C Zhan, Q Wang, L Tan - … Therapy-Nucleic Acids, 2022 - cell.com
Lung adenocarcinoma (LUAD) is one of the most common malignancies worldwide. Combination
chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant …
chemotherapy with cisplatin (CDDP) plus pemetrexed (PEM) remains the predominant …
Perioperative toripalimab+ platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival …
…, W Fang, W Xing, Q Chen, J Mei, L Yang, L Tan… - 2023 - ascopubs.org
425126 Background: Adjuvant and neoadjuvant immunotherapy have been approved by US
FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment…
FDA to treat early-stage NSCLC. However, the optimal neoadjuvant and adjuvant treatment…
[HTML][HTML] Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial
…, J Gu, T Jiang, D Lin, Z Huang, C Du, K Wu, L Tan… - Nature Medicine, 2023 - nature.com
Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally
advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a …
advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a …
Landscape and dynamics of single tumor and immune cells in early and advanced‐stage lung adenocarcinoma
…, S Xu, C Zhan, J Xi, Q Wang, L Tan - Clinical and …, 2021 - Wiley Online Library
Background Lung adenocarcinoma (LUAD) patients with different American Joint Committee
on Cancer stages have different overall 5‐year survival rates. The tumor microenvironment (…
on Cancer stages have different overall 5‐year survival rates. The tumor microenvironment (…
[HTML][HTML] HIF-1α switches the functionality of TGF-β signaling via changing the partners of smads to drive glucose metabolic reprogramming in non-small cell lung …
…, J Xi, Z Lin, C Zhan, W Jiang, Q Wang, L Tan - Journal of Experimental …, 2021 - Springer
Background Most cancer cells have fundamentally different metabolic characteristics, particularly
much higher glycolysis rates than normal tissues, which support the increased demand …
much higher glycolysis rates than normal tissues, which support the increased demand …